RecruitingPhase 3NCT07275827

Comparative Study Evaluating Safety and Effectiveness of ( Proton Pump Inhibitor Versus Vonoprazan ) Based Triple Therapy With or Without Zinc to Eradicate H. Pylori Infection

Sponsor

Tanta University

Enrollment

88 participants

Start Date

Feb 1, 2026

Study Type

INTERVENTIONAL

Conditions

Helicobacter Pylori Infections

Summary

this Study Evaluating Safety and Effectiveness of (Proton Pump Inhibitor versus Vonoprazan) Based Triple Therapy with or without Zinc to Eradicate H. pylori Infection

Eligibility

Min Age: 19 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Vonoprazan + amoxicillin + clarithromycin, a drug called proton pump inhibitor + amoxicillin, and others for people with helicobacter pylori infections. The study is currently recruiting participants at 1 location. People eligible for this study include aged 19 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGzinc sulfate

Effect of using Zinc in Helicobacter pylori Treatment

DRUGVonoprazan + amoxicillin + clarithromycin

Effect of using Vonoprazan + amoxicillin + clarithromycin in Helicobacter pylori Treatment

DRUGproton pump inhibitor + amoxicillin

Effect of using proton pump inhibitor + amoxicillin in Helicobacter pylori Treatment

Locations(1)

National Liver Institute

Shibīn al Kawm, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07275827

Related Trials

Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection

NCT072939101 location

Effect of Bismuth Add-on to Dual Therapy for Helicobacter Pylori Eradication

NCT075769591 location

Efficacy and Safety of 14-Day Vonoprazan-Based Dual Therapy Versus Quadruple Therapy for Helicobacter Pylori Eradication: A Multicentre, Non-Inferiority Randomized Controlled Trial

NCT071791592 locations

Eradication of Helicobacter Pylori Improves Metabolic Syndrome Through Modulation of Gut Microbiota.

NCT073069881 location

Registry for the Management of Helicobacter Pylori Infection in Shandong Province

NCT073354062 locations